Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5498019 | 0.83 | MAP4K4 (0.45) | GAAPOLBMAP4K4PDE4APDE4B | |
| SCHEMBL11409791 | 0.82 | EZH2 (0.32) | GAAPOLBEZH2 | |
| SCHEMBL10965997 | 0.80 | KDM4E (0.35) | ALDH1A1MAPK1 | |
| SCHEMBL3848429 | 0.80 | MAP4K4 (0.43) | GAAPOLBMAP4K4MAPK14PIN1 | |
| SCHEMBL7054403 | 0.78 | GAA (0.64) | GAAPOLBMAP4K4PDE4APDE4B | |
| SCHEMBL8431375 | 0.76 | GAA (0.62) | GAAPOLBMAP4K4PDE4APDE4B | |
| SCHEMBL920567 | 0.76 | GAA (0.46) | GAAPOLBMAP4K4PDE4APDE4B | |
| SCHEMBL1222332 | 0.76 | ALOX5AP (0.37) | GAAPIN1SMN1; SMN2ALDH1A1LRRK2 | |
| SCHEMBL920742 | 0.74 | POLB (0.66) | GAAPOLBMAP4K4PDE4APDE4B | |
| SCHEMBL152163 | 0.73 | LTA4H (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | claimed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | claimed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| EP-1034164-A4 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2001-07-11 | — | — | EP | claimed |
| EP-1034164-A1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (US) | 2000-09-13 | — | — | EP | claimed |
| WO-1999026921-A1 | SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | claimed |
| EP-0662477-A1 | Heterobicyclic compounds with fungicidal activity | ISAGRO S.p.A. (IT) | 1995-07-12 | — | — | EP | claimed |
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-6399731-B2 | SYNTHESIZING POLYMERS USING PHOSPHOROUS-CONTAINING ADDITION-FRAGMENTATION CHAIN TRANSFER AGENTS; MOLECULAR WEIGHT CONTROL | THE UNIVERSITY OF AKRON | 2002-06-04 | — | — | US | disclosed |
| US-20020016424-A1 | Synthesizing polymers using phosphorous-containing addition-fragmentation chain transfer agents; molecular weight control | AKRON, THE UNIVERSITY OF | 2002-02-07 | — | — | US | disclosed |
| EP-1034164-A1 | SUBSTITUTED BETA-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (US) | 2000-09-13 | — | — | EP | disclosed |
| WO-2000020465-A1 | NOVEL CHAIN TRANSFER AGENTS | THE UNIVERSITY OF AKRON (US) | 2000-04-13 | — | — | WO | disclosed |
| WO-1999026921-A1 | SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| US-5716974-A | TREATING FUNGAL PLANT DISEASES | ISAGRO S.P.A. (IT) | 1998-02-10 | — | — | US | disclosed |
| EP-0662477-A1 | Heterobicyclic compounds with fungicidal activity | ISAGRO S.p.A. (IT) | 1995-07-12 | — | — | EP | disclosed |
| US-4414210-A | 2-Hydroxyarylethyltriazole fungicides | ROHM AND HAAS COMPANY (US) | 1983-11-08 | — | — | US | disclosed |
| US-4413003-A | FUNGICIDES | ROHM AND HAAS COMPANY (US) | 1983-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | GAA 420/4885POLB 881/4885MAP4K4 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.